Membership Home Portfolio Stocks Bonds Funds ETFs CEFs Markets Tools Real Life Finance Discuss
Home>Topics>>Celgene And The Race To Cure Multiple Myeloma

Celgene And The Race To Cure Multiple Myeloma

Healthcare Sector and Stocks Analysis from Seeking Alpha

Fri, 15 Feb 2013

By Peter Geschek : Pomalyst In February the FDA approved Pomalyst (pomalidomide) developed by Celgene ( CELG ) for the treatment of patients with multiple myeloma whose disease progressed after being treated with other cancer drugs, like Celgene's Revlimid or Johnson & Johnson/Takeda's Velcade. ...

Read the rest of this article on Healthcare Sector and Stocks Analysis from Seeking Alpha

Related Videos

  1. Why J&J Bought a Big Piece of Elan

    Fri, 4 Dec 2009

    Morningstar's Damien Conover and Alex Morozov discuss what J&J's stake in biotech Elan means for both companies.

Content Partners
Site Directory Site Map Our Products
Corrections Help Advertising Opportunities Licensing Opportunities Glossary RSS Mobile Portfolio Affiliate Careers Company News
International Sites: Australia Canada China France Germany Hong Kong Italy The Netherlands Norway Spain U.K. Switzerland India Finland
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.

© Copyright 2013 Morningstar, Inc. All rights reserved. Please read our Terms of Useand Privacy Policy.Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.